Ask a pharma brand's trade marketing head whether product is leaking out of the channels it was allocated to, and the answer is almost always yes. Ask them which distributor, which state, or which tender is responsible, and the conversation usually stops. Pharma diversion is one of the best-documented open secrets in Indian supply chains — widely assumed, rarely proven, and almost never prosecuted, because the product itself is completely genuine. There's no counterfeit to seize and no spurious batch to recall. A box of medicine simply turns up somewhere it was never supposed to be, sold by someone who was never supposed to sell it, at a price that only makes sense if it travelled through a channel it wasn't allocated to.
That distinction matters. Ratifye's earlier piece on the ₹1 lakh crore supply chain blind spot covered grey market diversion across FMCG, alco-bev, and pharma broadly. Pharma deserves its own treatment, because the mechanics are different in one critical way: India's pharmaceutical pricing is partly government-controlled, partly free-market, and partly a function of who the buyer is — a government tender, a hospital, a doctor, or a retail patient. Every one of those price gaps is a diversion incentive waiting to be exploited.
Why Pharma Diversion Is Structurally Different
In most FMCG categories, diversion happens because of regional price variation — a brand sets different trade prices in different states, and a distributor with surplus stock in a cheaper territory ships it into a pricier one for margin. Pharma has that same mechanism, but layered on top of it are at least three pricing systems operating simultaneously on the same molecule: the DPCO ceiling price for drugs on the National List of Essential Medicines, the free-market price for everything outside that list, and a separate, usually much lower, institutional or tender price negotiated directly with government hospitals, armed forces medical stores, or large private hospital chains buying in bulk.
A single SKU can legitimately exist at three or four different price points depending on who is buying it and why. That's not a flaw in the system — tiered pricing is how India keeps essential medicines affordable while still letting manufacturers earn commercial margins elsewhere. But every one of those price tiers creates an arbitrage opportunity for anyone positioned between the manufacturer and the eventual patient, and in a market with over 850,000 retail pharmacies and a wholesale network that runs several layers deep, there are a great many people positioned exactly there.
Five Routes Medicine Actually Leaks
Diversion in pharma isn't one failure mode. It's at least five distinct mechanisms, each with its own economics, its own participants, and its own blind spot in a standard supply chain system.
Why Distributor Scheme Discounts Make the Incentive Worse
Most pharma companies run volume-linked scheme discounts — a distributor who commits to and achieves a quarterly volume target earns a retrospective discount or additional free stock on top of their regular margin. That's a completely standard, legitimate trade practice. But it also means a distributor sitting just short of their volume slab has every incentive to move stock fast, including into a neighbouring territory, because clearing the slab unlocks a discount that applies to their entire quarter's purchases — not just the marginal units. The diversion decision isn't made by a criminal network; it's made by a perfectly ordinary distributor doing the math on their own scheme targets.
Why Batch-Level Tracking Can't Prove Any of This
CDSCO's Schedule H track-and-trace mandate requires batch and expiry data at the secondary and tertiary packaging level, and most manufacturers already comply. The problem is that batch-level data describes the product, not the specific unit's journey. Every strip in a batch of 50,000 carries the identical batch number. When a diverted unit is scanned anywhere in the supply chain — a pharmacy in a state it was never allocated to, a hospital it was never tendered to — the scan reads as completely valid. The batch exists, the expiry is current, the product is genuine. Nothing in a batch-based system distinguishes a unit that followed its intended channel from one that didn't, because the system was never designed to track units individually in the first place.
What Unit-Level Serialization Actually Surfaces
Serialization assigns a unique serial — an SGTIN — to every individual pack, not just every batch. That single change turns an invisible problem into a traceable one. When a specific SGTIN is commissioned, it can be tagged not just with its batch and expiry, but with the channel it was allocated to: institutional tender, export market, physician sample, or a named distributor's territory. When that exact unit is then scanned anywhere downstream — by a pharmacist, a patient, or a field auditor — the scan event is geo-tagged and timestamped, and compared against its intended destination in real time.
| Diversion Route | What a Batch Number Shows | What an SGTIN Scan Shows |
|---|---|---|
| Tender stock sold to trade | Valid batch, current expiry — looks normal | Unit was commissioned for government tender allocation, scanned at a private retail pharmacy |
| Physician sample resale | Indistinguishable from trade stock once relabelled | Unit was commissioned as a non-saleable physician sample, scanned at point of retail sale |
| Inter-state distributor arbitrage | No territory data at all | Unit allocated to Distributor A's territory, scanned 600km outside that geo-fence |
| Export re-import | Same batch as domestic stock if manufactured together | Unit commissioned for an export market, scanned inside India |
What to Do Once You Can Actually See It
Detection is only half the problem — what a brand does with a confirmed diversion event is a contractual and commercial question, not just a legal one. Most distributor agreements already prohibit out-of-territory sales, but without unit-level evidence, enforcing that clause means relying on circumstantial trade data or a competitor's complaint, neither of which holds up well in a commercial dispute. A GPS-stamped, timestamped scan event tied to a specific SGTIN and a specific distributor's allocation is a different category of evidence: it's precise enough to raise in a distributor review, withhold a scheme payout against, or escalate to termination, without having to prove intent — only location.
The brands that get ahead of this don't wait for a channel conflict complaint to go looking for diversion. They build the geo-fence and channel allocation into the serialization layer from day one, so every scan is either consistent with the unit's intended journey or immediately flagged if it isn't. That shifts diversion detection from an occasional, reactive investigation into a standing, real-time control — the same shift CDSCO's own track-and-trace mandate is pushing the industry toward for counterfeit detection, just applied to a different problem with the same underlying data.
Find out where your product is actually going.
Ratifye's geo-fence diversion detection ties every unit to its intended channel and flags the exact scan that breaks it — GPS-stamped, timestamped, and ready to put in front of a distributor. Most pharma brands identify their first diversion corridor within 30 days.
See diversion detectionSources: National Pharmaceutical Pricing Authority (NPPA) and Drug Prices Control Order (DPCO) 2013 provisions on scheduled and non-scheduled formulation pricing; Amar Ujala reporting on the multi-state physician sample diversion racket (2026); Tribune India reporting on diverted Punjab government-supply medicines; industry estimates on grey market diversion as a share of brand revenue across FMCG, alco-bev, and pharma categories in India. Figures are the most recent publicly available estimates at time of writing and are cited for directional reference; consult primary sources and legal counsel for compliance or enforcement decisions.
